UA43385C2 - Спосіб лікування синдрому дефіциту уваги/гіперактивності - Google Patents

Спосіб лікування синдрому дефіциту уваги/гіперактивності

Info

Publication number
UA43385C2
UA43385C2 UA97073620A UA97073620A UA43385C2 UA 43385 C2 UA43385 C2 UA 43385C2 UA 97073620 A UA97073620 A UA 97073620A UA 97073620 A UA97073620 A UA 97073620A UA 43385 C2 UA43385 C2 UA 43385C2
Authority
UA
Ukraine
Prior art keywords
treatment
hyperactivity syndrome
attention deficiency
deficiency
attention
Prior art date
Application number
UA97073620A
Other languages
English (en)
Inventor
Джон Х. ХІЛАЙГЕНСТЕЙН
Гарі Д. ТОЛЛЕФСОН
Original Assignee
Елі Ліллі Енд Компані
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23463572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA43385(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Елі Ліллі Енд Компані, Эли Лилли Энд Компани filed Critical Елі Ліллі Енд Компані
Publication of UA43385C2 publication Critical patent/UA43385C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

Томоксетин, інгібітор зворотного захоплення норепінефріну, застосовують для лікування синдрому дефіциту уваги/гіперативності.
UA97073620A 1995-01-11 1996-04-01 Спосіб лікування синдрому дефіциту уваги/гіперактивності UA43385C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/371,341 US5658590A (en) 1995-01-11 1995-01-11 Treatment of attention-deficit/hyperactivity disorder
PCT/US1996/000091 WO1996021430A1 (en) 1995-01-11 1996-01-04 Treatment of attention-deficit/hyperactivity disorder

Publications (1)

Publication Number Publication Date
UA43385C2 true UA43385C2 (uk) 2001-12-17

Family

ID=23463572

Family Applications (1)

Application Number Title Priority Date Filing Date
UA97073620A UA43385C2 (uk) 1995-01-11 1996-04-01 Спосіб лікування синдрому дефіциту уваги/гіперактивності

Country Status (28)

Country Link
US (1) US5658590A (uk)
EP (1) EP0721777B1 (uk)
JP (2) JPH10512262A (uk)
KR (1) KR19980701276A (uk)
CN (2) CN1168095A (uk)
AT (1) ATE222757T1 (uk)
AU (1) AU688665B2 (uk)
BR (1) BR9606903A (uk)
CA (1) CA2209735C (uk)
CZ (1) CZ292226B6 (uk)
DE (2) DE122005000011I2 (uk)
DK (1) DK0721777T3 (uk)
ES (1) ES2181845T3 (uk)
FI (1) FI119354B (uk)
FR (1) FR10C0041I2 (uk)
HU (1) HU227306B1 (uk)
LU (1) LU91238I2 (uk)
NL (1) NL300180I2 (uk)
NO (2) NO317027B1 (uk)
NZ (1) NZ301500A (uk)
PL (1) PL187573B1 (uk)
PT (1) PT721777E (uk)
RO (1) RO118374B1 (uk)
RU (1) RU2163802C2 (uk)
SI (1) SI0721777T1 (uk)
TR (1) TR199700627T1 (uk)
UA (1) UA43385C2 (uk)
WO (1) WO1996021430A1 (uk)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
GB9613243D0 (en) * 1996-06-25 1996-08-28 Britannia Pharmaceuticals Ltd Attention deficit hyperactive disorder
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
WO1999015177A1 (en) * 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US5902797A (en) * 1997-11-10 1999-05-11 Beth Israel Deaconess Medical Center Nutritional supplement for use in the treatment of attention deficit
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
JP2002511414A (ja) * 1998-04-09 2002-04-16 ファルマシア・アンド・アップジョン・カンパニー 神経疾患のための新しい治療
KR20010103655A (ko) * 1998-11-09 2001-11-23 케네쓰 제이. 울코트 키메라 항-ｃｄ２０항체를 이용한 순환성 종양세포와관련된 혈액학적 악성종양의 치료법
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6400978B1 (en) 1999-10-29 2002-06-04 The Mclean Hospital Corporation Method and apparatus for detecting mental disorders
US6898455B2 (en) * 1999-10-29 2005-05-24 The Mclean Hospital Corporation Method for providing optimal drug dosage
PL357042A1 (en) * 2000-03-07 2004-07-12 Eli Lilly And Company Treatment of psoriasis
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
CZ2004709A3 (cs) * 2001-12-11 2004-10-13 Eliálillyáandácompany Použití inbibitorů vychytávání norepinefrinu pro léčení poruch kognitivních funkcí
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
US7384941B2 (en) 2002-08-23 2008-06-10 Eli Lilly And Company 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
WO2005011583A2 (en) * 2003-07-28 2005-02-10 Leslie Joe Dunaway Treatment of allergic rhinitis and asthma
CA2536161A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
EP1660064A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
WO2005065673A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
MXPA06013762A (es) * 2004-05-27 2007-02-08 Warner Lambert Co Combinacion de atomoxetina y un agonista del receptor 5t1a para el tratamiento de trastorno de hiperactividad con deficit de atencion y otros trastornos.
US7378553B2 (en) * 2004-06-28 2008-05-27 Teva Pharmaceutical Fine Chemicals S.R.L. Isolated atomoxetine impurity, processes for the preparation of atomoxetine impurities and their use as reference standards
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
WO2006020348A2 (en) 2004-07-22 2006-02-23 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of atomoxetine hydrochloride
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ589750A (en) 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
CA2600609A1 (en) * 2005-04-05 2006-10-12 Teva Pharmaceutical Fine Chemicals S.R.L. Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
CA2629800A1 (en) * 2005-11-23 2007-05-31 Thomas G. Gant Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
WO2007065655A1 (en) 2005-12-07 2007-06-14 Neurosearch Sweden Ab Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission
US20080020387A1 (en) * 2006-03-31 2008-01-24 Lawrence Donald G Biomarker-optimized adhd treatment
US20080146675A1 (en) * 2006-04-05 2008-06-19 Eugenio Castelli Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
US20080031932A1 (en) * 2006-08-04 2008-02-07 Watson Laboratories, Inc. Transdermal atomoxetine formulations and associated methods
US20080145318A1 (en) * 2006-12-13 2008-06-19 Midha Kamal K Atomoxetine formulations and associated methods
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
CA2735934C (en) 2008-09-05 2014-01-07 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (adhd)
RU2395313C2 (ru) * 2008-10-15 2010-07-27 Татьяна Прохоровна Тетерина Способ коррекции синдрома дефицита внимания и гиперактивности
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
RU2428226C1 (ru) * 2009-12-31 2011-09-10 Учреждение Российской академии медицинских наук Научный центр проблем здоровья семьи и репродукции человека Сибирского отделения РАМН Применение атомоксетина гидрохлорида, импульсного низкоинтенсивного электромагнитного поля и кислородного коктейля у детей с синдромом дефицита внимания с гиперактивностью
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
MX2021000431A (es) 2011-03-23 2022-10-28 Ironshore Pharmaceuticals & Dev Inc Metodos y composiciones para el tratamiento de trastorno por deficit de atencion.
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
MX356727B (es) 2012-02-08 2018-06-12 Supernus Pharmaceuticals Inc Formulaciones de liberacion modificada de viloxacina.
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US9326935B2 (en) 2013-11-08 2016-05-03 Eli Lilly And Company Atomoxetine solution
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994486A (en) * 1989-05-31 1991-02-19 Abbott Laboratories Dopaminergic compounds
US5457121A (en) * 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine

Also Published As

Publication number Publication date
ES2181845T3 (es) 2003-03-01
DK0721777T3 (da) 2002-10-07
TR199700627T1 (xx) 1998-01-21
HUP9801283A2 (hu) 1999-06-28
KR19980701276A (ko) 1998-05-15
NO2005006I2 (no) 2006-06-19
CA2209735A1 (en) 1996-07-18
AU688665B2 (en) 1998-03-12
NZ301500A (en) 2000-07-28
FI119354B (fi) 2008-10-31
CN1168095A (zh) 1997-12-17
EP0721777A2 (en) 1996-07-17
RU2163802C2 (ru) 2001-03-10
JP2005325139A (ja) 2005-11-24
EP0721777B1 (en) 2002-08-28
JPH10512262A (ja) 1998-11-24
DE69623141D1 (de) 2002-10-02
DE69623141T2 (de) 2003-04-24
FR10C0041I1 (uk) 2010-10-15
BR9606903A (pt) 1997-10-21
MX9705117A (es) 1997-10-31
CN1781480A (zh) 2006-06-07
NL300180I1 (nl) 2005-05-02
PT721777E (pt) 2002-11-29
NO973170D0 (no) 1997-07-08
ATE222757T1 (de) 2002-09-15
HU227306B1 (en) 2011-03-28
NL300180I2 (nl) 2005-08-01
HUP9801283A3 (en) 1999-09-28
PL321273A1 (en) 1997-11-24
SI0721777T1 (en) 2003-02-28
NO973170L (no) 1997-09-02
CZ292226B6 (cs) 2003-08-13
FI972922A0 (fi) 1997-07-09
DE122005000011I1 (de) 2005-06-23
NO317027B1 (no) 2004-07-26
WO1996021430A1 (en) 1996-07-18
US5658590A (en) 1997-08-19
PL187573B1 (pl) 2004-08-31
DE122005000011I2 (de) 2006-02-09
LU91238I2 (fr) 2006-07-03
AU4693896A (en) 1996-07-31
FI972922L (fi) 1997-07-09
FR10C0041I2 (uk) 2011-04-29
EP0721777A3 (en) 1997-03-05
CZ214597A3 (cs) 1998-01-14
CA2209735C (en) 2002-10-01
RO118374B1 (ro) 2003-05-30

Similar Documents

Publication Publication Date Title
UA43385C2 (uk) Спосіб лікування синдрому дефіциту уваги/гіперактивності
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
EA200000351A1 (ru) Лечение кондуктивных нарушений
EA199800152A1 (ru) Лечение синдрома дефицита внимания/гиперактивности
EA199700170A1 (ru) Способ получения некоторых азациклогексапетидов
PT942751E (pt) Composicoes para o tratamento de neuropatias perifericas contendo antiodepressivos e/ou inibidores da monoamino-oxidase e/ou vitamina b12 e/ou precursores ou indutores de neurotransmissores
DE59202663D1 (de) Verwendung eines UV-Strahlers zur Behandlung von Oberflächen.
MY136367A (en) Treatment of cognitive failure
WO2001066101A3 (en) Treatment of psoriasis
BR0115301A (pt) Uso de um inibidor seletivo da recaptação de norepinefrina
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
PT1054671E (pt) Nova utilizacao da ropivacaina para o controlo da dor
SE0003126D0 (sv) Method of treatment
BR0112460A (pt) Método para tratamento de sépsis
NO20006314L (no) Prenyltransferase-inhibitorer
NO984190L (no) FremgangsmÕte for behandling av insomnia
DE69927985D1 (de) Verwendung von misoprostol oder/und misoprostol saüre zur herstellung eines arzneimittels zur behandlung weiblicher sexualer störung